tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Theravance Biopharma Inc

TBPH
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
17.030USD
0.0000.00%
์ข…๊ฐ€ย 09-23 16:00๏ผˆET๏ผ‰
884.20M์‹œ๊ฐ€์ด์•ก
7.47P/E TTM

Theravance Biopharma Inc ์ •๋ณด ํšŒ์‚ฌ

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Theravance Biopharma Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ TBPH
ํšŒ์‚ฌ ์ด๋ฆ„Theravance Biopharma Inc
์ƒ์žฅ์ผMay 16, 2014
CEOWinningham (Rick E)
์ง์› ์ˆ˜97
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 16
์ฃผ์†ŒUgland House, South Church Street
๋„์‹œGEORGE TOWN
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Cayman Islands
์šฐํŽธ ๋ฒˆํ˜ธKY1-1104
์ „ํ™”16508086000
์›น์‚ฌ์ดํŠธhttps://www.theravance.com/
์ข…๋ชฉ ์ฝ”๋“œ TBPH
์ƒ์žฅ์ผMay 16, 2014
CEOWinningham (Rick E)

Theravance Biopharma Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.50M
-1.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
131.26K
-6.06%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
114.19K
-7.10%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
93.11K
-6.72%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
-8.10%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
57.06K
-12.28%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
-14.26%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Ms. Rhonda F. Farnum
Ms. Rhonda F. Farnum
Senior Vice President - Commercial and Medical Affairs, Chief Business Officer
Senior Vice President - Commercial and Medical Affairs, Chief Business Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.50M
-1.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
131.26K
-6.06%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
114.19K
-7.10%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
93.11K
-6.72%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
-8.10%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
57.06K
-12.28%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Theravance Biopharma Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Theravance Biopharma Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Rick E. Winningham

Theravance Biopharma Inc(TBPH)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Theravance Biopharma Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 333๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 53.21M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 103.22%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -3281733.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ